Mirati Therapeutics’ KRAS Blocker Shrinks Tumors in Advanced Colon Cancer Patients

Mirati Therapeutics’ adagrasib reduced tumors in 22 percent of colorectal cancer patients with a KRAS G12C gene mutation in a phase 1/2 trial.

Adagrasib combined with another anticancer therapy, cetuximab, reduced tumors by 43 percent in the early/mid-stage trial, the California-based company said.

If approved, adagrasib would compete with Amgen’s potential blockbuster cancer drug, Lumakras (sotorasib), which the FDA approved in May for the same indication.